AVDL - Avadel Pharmaceuticals names new Chief Commercial Officer

Avadel Pharmaceuticals (AVDL) appointed 25-years industry veteran Richard Kim to the newly formed role of Chief Commercial Officer for leading all aspects of the U.S. commercial launch of the company’s lead program, once-nightly FT218, pending regulatory approval.Mr. Kim states, "It isn’t often that a new product has the potential to offer such a significant advancement in patient care for an established multi-billion dollar market. If approved, I believe FT218 will be the preferred choice for sodium oxybate drug therapy and provide a potentially life-changing option for narcolepsy patients, while creating value for our shareholders."Most recently, he served as President of U.S. Commercial & Strategic Marketing at Intercept Pharmaceuticals.Shares trading 0.93% higher premarket.

For further details see:

Avadel Pharmaceuticals names new Chief Commercial Officer